Anzeige
Mehr »
Login
Samstag, 27.07.2024 Börsentäglich über 12.000 News von 684 internationalen Medien
BRANDNEUE Gold-Entdeckung: OMEGA stößt auf HOCHGRAD-Gold! 18,98 m @ 6,22 g/t Gold! TA-Preis "STARKER-KAUF"
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A400AS | ISIN: US74019P2074 | Ticker-Symbol: PBS0
Frankfurt
26.07.24
16:00 Uhr
9,150 Euro
+0,100
+1,10 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PRECISION BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
PRECISION BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,1509,45026.07.
9,1009,50026.07.

Aktuelle News zur PRECISION BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
03.07.Kwangdong Pharma acquires stake in Precision Bio2
01.07.PRECISION BIOSCIENCES INC - S-8, Securities to be offered to employees in employee benefit plans1
01.07.Precision BioSciences joins Russell Microcap Index2
10.06.PRECISION BIOSCIENCES INC - 8-K, Current Report1
22.05.DelveInsight Business Research, LLP: CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Register Stunning Growth by 2032, Predicts DelveInsight | Key Companies - AUTOLUS THERAPEUTICS, CELLECTIS, WUGEN, SERVIER, ALLOGENE, PRECISION BIOSCIENCES505The CAR T-cell therapy market for acute lymphoblastic leukemia is poised for substantial growth, driven by the anticipated launch of therapies such as OBECABTAGENE AUTOLEUCEL (OBE-CEL), UCART22...
► Artikel lesen
16.05.Deep Dive Into Precision BioSciences Stock: Analyst Perspectives (4 Ratings)2
13.05.Precision BioSciences Inc reports results for the quarter ended in March - Earnings Summary-
13.05.Quarterly Results Takes Precision BioSciences Higher1
13.05.Precision BioSciences Reports Profit From Cont. Ops. In Q12
13.05.Precision BioSciences GAAP EPS of $1.70, revenue of $17.58M beats by $11.56M1
13.05.PRECISION BIOSCIENCES INC - 10-Q, Quarterly Report1
13.05.Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update105DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies...
► Artikel lesen
10.05.Precision BioSciences Q1 Earnings Preview2
08.05.PRECISION BIOSCIENCES INC - 8-K, Current Report1
07.05.Why Precision BioSciences Is Rising In Pre-market?2
01.05.Precision BioSciences, Inc.: Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024265Data to be presented will highlight latest preclinical safety data for PBGENE-HBV in preparation for regulatory filings in 2024 Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing...
► Artikel lesen
16.04.Eli Lilly subsidiary, Precision Biosciences end gene therapy collaboration19
16.04.PRECISION BIOSCIENCES INC - 8-K, Current Report3
01.04.Precision Biosciences, Mesoblast, Pulse Biosciences among healthcare movers10
27.03.Precision BioSciences Inc reports results for the quarter ended in December - Earnings Summary1
Seite:  Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1